Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea

PloS One
Jung Yeon HeoJoon Young Song

Abstract

Although the 13-valent pneumococcal conjugate vaccine (PCV13) showed good efficacy against pneumococcal disease in the the CAPiTA trial, the 23-valent pneumococcal polysaccharide vaccination (PPSV23) program has been ongoing for older adults aged ≥ 65 years in Korea since May of 2013. This study aimed to evaluate the cost-effectiveness of the current vaccination strategy (a single-dose PPSV23 vaccination) compared to a single-dose PCV13 vaccination and sequential PCV13-PPSV23 vaccinations in the elderly population aged ≥ 65 years. Using a Markov model, the incremental cost-effectiveness ratios (ICERs) of three vaccination strategies were assessed in a societal context. The transition probabilities, utility weights to estimate quality adjusted life year (QALY), and disease treatment costs were either calculated or cited from published data and the Health Insurance Review and Assessment Service. Simulations were performed in hypothetical cohorts of Korean adults aged ≥ 19 years. The vaccine effectiveness of PPSV23 was cited from a Cochrane Review report, while PCV13 effectiveness data were gathered from the CAPiTA trial. Current PPSV23 vaccination strategies were cost-effective (ICER, $25,786 per QALY). However, the administratio...Continue Reading

References

Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Apr 7, 2004·The European Respiratory Journal·B ChristensonA Ortqvist
Aug 31, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Angel Vila-CórcolesUNKNOWN EVAN Study Group
Jul 3, 2007·The Journal of Infection·Sae Yoon KeeWoo Joo Kim
Jan 7, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Anke HussMatthias Egger
Aug 14, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M GuevaraJ Castilla
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Dec 18, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nicholas D WalterUNKNOWN Active Bacterial Core Surveillance Team
Feb 24, 2012·JAMA : the Journal of the American Medical Association·Kenneth J SmithRichard K Zimmerman
Jul 26, 2012·Health Economics Review·Alexander KuhlmannJ-Matthias Graf von der Schulenburg
Oct 3, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Yiling JiangXavier Bresse
Jan 9, 2013·Human Vaccines & Immunotherapeutics·Sara BoccaliniPaolo Bonanni
Jun 19, 2013·Journal of Korean Medical Science·Kwang Ha YooKi Suck Jung
Jan 30, 2014·Infection & chemotherapy·Joon Young SongMoon H Nahm
Aug 12, 2014·The Lancet Global Health·Keith P Klugman
Mar 19, 2015·The New England Journal of Medicine·Marc J M BontenDiederick E Grobbee
Jul 15, 2015·The European Respiratory Journal·Marie-Josée J MangenG Ardine de Wit
Oct 21, 2015·Reproduction in Domestic Animals = Zuchthygiene·J Y KimM J Yoon

❮ Previous
Next ❯

Citations

Nov 9, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Chun-Yi LuYu-Fan Ho

❮ Previous
Next ❯

Software Mentioned

CAPiTA

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.